Status:
COMPLETED
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
Lead Sponsor:
Christine Mauz-Körholz
Conditions:
Lymphoma
Eligibility:
All Genders
Up to 17 years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-ray...
Detailed Description
OBJECTIVES: * Determine the safety and efficacy of intensified etoposide administered as a part of OEPA combination chemotherapy (vincristine, etoposide, prednisone, and doxorubicin hydrochloride) in...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of classic Hodgkin's lymphoma (HL)
- Intermediate or advanced disease, including the following stages:
- Stage I
- Stage IIA, IIB, IIE, or IIBE
- Stage IIIA or IIIBE
- Stage IV
- PATIENT CHARACTERISTICS:
- No other concurrent malignancies
- No severe concurrent diseases (e.g., immune deficiency syndrome)
- PRIOR CONCURRENT THERAPY:
- No prior chemotherapy or radiotherapy
- Pre-phase therapy for large mediastinal tumor allowed
Exclusion
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2005
Estimated Enrollment :
648 Patients enrolled
Trial Details
Trial ID
NCT00416832
Start Date
November 1 2002
End Date
December 1 2005
Last Update
March 26 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.